Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case–control study

OBJECTIVE: The SAVOR TIMI–53 study reported a significant increase in the risk of hospitalisation for heart failure (HF) in patients treated with a DPP-4 inhibitor (DPP-4i) in comparison with placebo. A recent case-control study in part confirmed this risk signal. Our aim was to compare the occurren...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:BMJ Open
Prif Awduron: Giorda, Carlo B, Picariello, Roberta, Tartaglino, Barbara, Marafetti, Lisa, Di Noi, Fabiana, Alessiato, Annalisa, Costa, Giuseppe, Gnavi, Roberto
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2015
Pynciau:
Diabetes and Endocrinology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4458680/
https://ncbi.nlm.nih.gov/pubmed/26048211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2015-007959
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg